Insider Selling: CareDx, Inc (NASDAQ:CDNA) Director Sells 29,136 Shares of Stock

CareDx, Inc (NASDAQ:CDNA) Director Christine Cournoyer sold 29,136 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $15.96, for a total transaction of $465,010.56. Following the sale, the director now owns 37,045 shares of the company’s stock, valued at $591,238.20. This trade represents a 44.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Christine Cournoyer also recently made the following trade(s):

• On Tuesday, May 6th, Christine Cournoyer sold 16,700 shares of CareDx stock. The stock was sold at an average price of $14.13, for a total transaction of $235,971.00.

CareDx Trading Up 0.5%

CDNA opened at $16.10 on Friday. CareDx, Inc has a 1-year low of $12.90 and a 1-year high of $34.84. The stock has a market capitalization of $896.46 million, a PE ratio of -5.96 and a beta of 2.27. The firm has a 50-day moving average price of $17.64 and a two-hundred day moving average price of $20.97.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.03. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. The firm’s revenue for the quarter was up 17.6% compared to the same quarter last year. On average, research analysts predict that CareDx, Inc will post -0.9 EPS for the current year.

Institutional Investors Weigh In On CareDx

Several institutional investors have recently modified their holdings of the business. PDT Partners LLC acquired a new stake in shares of CareDx during the 1st quarter worth approximately $1,244,000. Next Century Growth Investors LLC grew its position in shares of CareDx by 25.1% during the 1st quarter. Next Century Growth Investors LLC now owns 274,874 shares of the company’s stock worth $4,879,000 after buying an additional 55,127 shares during the period. Virtus Advisers LLC acquired a new stake in shares of CareDx during the 1st quarter worth approximately $720,000. Capital Fund Management S.A. grew its position in shares of CareDx by 4.9% during the 1st quarter. Capital Fund Management S.A. now owns 129,090 shares of the company’s stock worth $2,291,000 after buying an additional 6,085 shares during the period. Finally, Fuller & Thaler Asset Management Inc. grew its position in shares of CareDx by 3.9% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 23,925 shares of the company’s stock worth $425,000 after buying an additional 900 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CDNA shares. HC Wainwright reiterated a “neutral” rating and set a $25.00 target price on shares of CareDx in a research report on Monday, May 5th. The Goldman Sachs Group dropped their target price on shares of CareDx from $34.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Stephens reiterated an “overweight” rating and set a $40.00 target price on shares of CareDx in a research report on Monday, May 5th. Finally, StockNews.com cut shares of CareDx from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.